Back

Risk of incident renal cell carcinoma in patients with type 2 diabetes on sodium-glucose co-transporter-2 inhibitor users: a population-based cohort study

27 August 2023 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Diabetes and the heart (3) Diabetes and the Heart ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Gwo-Ping Jong

Chung Shan Medical University Hospital, Taichung (Taiwan)

6 More presentations in this session

Presentation thumbnail
Fifteen-year follow-up and impact of age and sex on cardiovascular outcomes in diabetes and non-diabetes patients without CAD
Doctor P. Thrane (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Impact of glycated hemoglobin A1c on cardiovascular risk in diabetes patients with and without coronary artery disease
Doctor M. Hansen (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
The impact of glycated hemoglobin A1c on cardiovascular risk in patients with and without coronary artery disease
Doctor K. Olesen (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Elevated remnant cholesterol in atherosclerotic cardiovascular disease in diabetes: a population-based prospective cohort study
Doctor B. Nilsson Wadstrom (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Effects of sodium-glucose contrasporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on vascular function and liver steatosis in diabetes
Doctor I. Ikonomidis (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Diabetes and the heart (3)

The Event

Event poster

ESC Congress 2023

27 August 2023 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Risk of Incident colorectal carcinoma in patients with type 2 diabetes on SGLT-2 inhibitor users: a population-based cohort study
thumbnail
Congress Presentation
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in cancer patients with diabetes mellitus
thumbnail
Congress Session
Repurposing anti-diabetic pharmacotherapy: the new cure for all evils?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources